Texas Retina Associates | ClinicalTrials HQ

7 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME	diabetic macular edema	Active, not recruiting	Phase 3	2026-10-08		NCT04108156
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)	Metaplasia, Neovascularization, Pathologic, Pathologic Processes, Pathological Conditions, Signs and Symptoms, age-related macular degeneration, choroidal neovascularization, eye disorder, macular degeneration, optic choroid disorder, retinal degeneration, retinal disorder, uveal disorder, wet macular degeneration	Recruiting	Phase 2 / Phase 3	2026-10-02		NCT07440225
Extension Study for the Port Delivery System With Ranibizumab (Portal)	Neovascular Age-Related Macular Degeneration	Recruiting	Phase 3	2026-09-28		NCT03683251
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56	wet macular degeneration	Active, not recruiting	Phase 3	2026-09-03		NCT06683742
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration	eye disorder, macular degeneration, retinal degeneration, retinal disorder, wet macular degeneration	Active, not recruiting	Phase 3	2026-06-01		NCT06864988
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK	Wet Age-related Macular Degeneration	Active, not recruiting	Phase 3	2026-04-29		NCT06556368
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration	Neovascular Age-related Macular Degeneration	Active, not recruiting	Phase 3	2025-06-17		NCT06495918